News Alkermes plc

Equities

ALKS

IE00B56GVS15

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
24.05 ^USD	-0.87%		0.00%	-13.30%

May. 02	UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating	MT
May. 01	Alkermes's Q1 Earnings, Revenue Grow But Miss Street View	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating	May. 02	MT
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk	May. 02	PR
Alkermes : Q1 2024 Earnings Call Script FINAL 5 1 2024	May. 02	PU
Alkermes : ALKS Q1 2024 Earnings Slides FINAL 5 1 2024	May. 02	PU
Alkermes's Q1 Earnings, Revenue Grow But Miss Street View	May. 01	MT
Transcript : Alkermes plc, Q1 2024 Earnings Call, May 01, 2024	May. 01
Alkermes: Q1 Earnings Snapshot	May. 01	AQ
Earnings Flash (ALKS) ALKERMES Reports Q1 Revenue $350.4M, vs. Street Est of $360.3M	May. 01	MT
Earnings Flash (ALKS) ALKERMES Posts Q1 EPS $0.43, vs. Street Est of $0.58	May. 01	MT
Alkermes plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01	CI
Alkermes plc Reports First Quarter 2024 Financial Results	May. 01	PR
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1	Apr. 24	PR
Alkermes to Report First Quarter Financial Results on May 1, 2024	Apr. 17	PR
Alkermes Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	Apr. 10	AQ
BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024	Apr. 09	AQ
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	Apr. 09	MT
Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study	Apr. 09	MT
Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia	Apr. 09	CI
Alkermes Insider Sold Shares Worth $292,740, According to a Recent SEC Filing	Mar. 19	MT
Baird Initiates Alkermes With Outperform Rating, Price Target is $37	Mar. 19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alkermes plc

Equities

ALKS

IE00B56GVS15

Summary

Filters